EGFR and non-small cell lung carcinoma: A retrospective study of 630 patients with metastatic EGFR-mutant NSCLC who received either gefitinib or erlotinib (as first or later line therapy) found a relationship between higher BMI and improved progression free survival (PFS) in patients with BMI ≥ 25 kg/m2 compared to BMI < 18.5 kg/m2 (15.6 months versus 8.5 months, respectively) and OS (28.8 months versus 26.7 months, respectively) (85).